Business objectives have changed

The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.

Inclusion Criteria:

Cohort 1 and 2

• Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect® MM registry
• Age ≥18 years
• Willing and able to provide signed informed consent
• Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel

Cohort 3

• Received 1L therapy for symptomatic active MM and subsequently has evidence of disease progression. Prior 1L MM treatment received, including anti-myeloma therapy, transplant, chemotherapy, radiation, and surgery, must be known.
• Initiated or intends to initiate 2L systemic therapy for MM after the first documented relapsed/refractory date (i.e. 1L PD).
• Enrollment date must be within 90 days of start date (or intended start date) of 2L systemic therapy.

Exclusion Criteria:

Cohort 1 and 2

- None

Cohort 3

• Patient's 1L MM treatment was for smoldering MM or MGUS, and not for symptomatic MM
• Currently active in any MM Registry, including but not limited to, the Connect® MM registry or another Celgene/BMS-Sponsored registry.
• Patients who have discontinued from Connect® MM or another Celgene/BMS-Sponsored registry could be considered for enrollment in Cohort 3, if inclusion and exclusion criteria are met.
• Currently enrolled or intending to enroll within 90 days in any interventional clinical trial in which any treatment is an investigational product that cannot be identified

Patients with newly diagnosed multiple myeloma and being treated in community or academic settings in the United States